Holen Sie sich die Stockscreener-App
19.40
0.56%
-0.11
Handel nachbörslich:
19.40
Schlusskurs vom Vortag:
$19.51
Offen:
$19.69
24-Stunden-Volumen:
294.67K
Relative Volume:
0.62
Marktkapitalisierung:
$983.05M
Einnahmen:
$62.02M
Nettoeinkommen (Verlust:
$-45.65M
KGV:
-21.09
EPS:
-0.92
Netto-Cashflow:
$-9.60M
1W Leistung:
-0.92%
1M Leistung:
-1.27%
6M Leistung:
+62.75%
1J Leistung:
+107.26%
1-Tages-Spanne:
$19.09
$19.69
1-Wochen-Bereich:
$18.45
$20.60
52-Wochen-Spanne:
$7.90
$21.03
Theravance Biopharma Inc Stock (TBPH) Company Profile
Firmenname
Theravance Biopharma Inc
Sektor
Branche
Telefon
650-808-6000
Adresse
UGLAND HOUSE, SOUTH CHURCH STREET, GEORGE TOWN, GRAND CAYMAN
Compare TBPH vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
TBPH
Theravance Biopharma Inc
|
19.40 | 988.62M | 62.02M | -45.65M | -9.60M | -0.92 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.02 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.65 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.54 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.48 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.42 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
Theravance Biopharma Inc Stock (TBPH) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-03 | Eingeleitet | Oppenheimer | Outperform |
| 2025-09-12 | Eingeleitet | B. Riley Securities | Buy |
| 2024-08-06 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2024-04-12 | Eingeleitet | BTIG Research | Buy |
| 2024-01-08 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2022-05-23 | Eingeleitet | SVB Leerink | Outperform |
| 2021-11-05 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2021-09-15 | Herabstufung | JP Morgan | Overweight → Underweight |
| 2021-08-25 | Herabstufung | Morgan Stanley | Overweight → Underweight |
| 2021-08-24 | Herabstufung | Cowen | Outperform → Market Perform |
| 2020-10-14 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2020-07-07 | Eingeleitet | JP Morgan | Overweight |
| 2020-06-15 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2020-05-13 | Eingeleitet | Cowen | Outperform |
| 2020-01-08 | Bestätigt | H.C. Wainwright | Buy |
| 2019-11-06 | Hochstufung | Robert W. Baird | Underperform → Neutral |
| 2019-10-29 | Eingeleitet | H.C. Wainwright | Buy |
| 2018-03-29 | Fortgesetzt | Piper Jaffray | Overweight |
| 2017-08-17 | Eingeleitet | Evercore ISI | Outperform |
| 2017-06-16 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2017-05-11 | Bestätigt | Needham | Buy |
| 2016-12-21 | Eingeleitet | Needham | Buy |
| 2016-11-03 | Eingeleitet | Piper Jaffray | Overweight |
| 2016-10-12 | Herabstufung | Robert W. Baird | Neutral → Underperform |
| 2016-08-03 | Herabstufung | BofA/Merrill | Neutral → Underperform |
| 2016-06-20 | Eingeleitet | Guggenheim | Buy |
| 2016-06-20 | Bestätigt | Leerink Partners | Outperform |
| 2016-05-12 | Eingeleitet | Leerink Partners | Outperform |
| 2016-05-05 | Herabstufung | BofA/Merrill | Buy → Neutral |
| 2015-02-03 | Hochstufung | Robert W. Baird | Underperform → Neutral |
Alle ansehen
Theravance Biopharma Inc Aktie (TBPH) Neueste Nachrichten
Baader Bank Aktiengesellschaft Invests $781,000 in Theravance Biopharma, Inc. $TBPH - MarketBeat
Theravance Biopharma Inc (NASDAQ:TBPH) Shows Strong Technical and Fundamental Momentum - ChartMill
Is Theravance Biopharma Inc. stock showing strong momentumJuly 2025 Macro Moves & Weekly Setup with ROI Potential - mfd.ru
Theravance Biopharma, Inc. (NASDAQ:TBPH) Receives Average Recommendation of "Buy" from Brokerages - MarketBeat
Precision Trading with Theravance Biopharma Inc. (TBPH) Risk Zones - Stock Traders Daily
RSI Check: Can Theravance Biopharma Inc sustain its profitabilityEarnings Risk Summary & Weekly High Return Stock Forecasts - baoquankhu1.vn
A Glimpse Into The Expert Outlook On Theravance Biopharma Through 4 Analysts - Benzinga
Theravance Biopharma's (TBPH) "Buy" Rating Reaffirmed at BTIG Research - MarketBeat
TBPH Stock: BTIG Reiterates 'Buy' Rating at $40 Target Price | T - GuruFocus
While shareholders of Theravance Biopharma (NASDAQ:TBPH) are in the black over 1 year, those who bought a week ago aren't so fortunate - simplywall.st
Is the Options Market Predicting a Spike in Theravance Biopharma Stock? - sharewise.com
Theravance Biopharma (NASDAQ:TBPH) Share Price Passes Above Fifty Day Moving AverageHere's What Happened - MarketBeat
Technical Reactions to TBPH Trends in Macro Strategies - Stock Traders Daily
Theravance Biopharma stock hits 52-week high at $21.01 By Investing.com - au.investing.com
Why Theravance Biopharma (TBPH) is a Top Momentum Stock for the Long-Term - Yahoo Finance
Profit Review: Is Theravance Biopharma Inc affected by consumer sentimentSell Signal & Safe Entry Zone Identification - baoquankhu1.vn
Theravance Biopharma stock hits 52-week high at $21.01 - Investing.com
Theravance Biopharma (NASDAQ:TBPH) Reaches New 1-Year HighHere's What Happened - MarketBeat
Neurogenic Orthostatic Hypotension (nOH) Global Clinical Trials Market Review 2025: Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End Point Status - GlobeNewswire Inc.
Why Theravance Biopharma (TBPH) is a Top Growth Stock for the Long-Term - sharewise.com
Theravance Biopharma, Inc. (NASDAQ:TBPH) Given Consensus Recommendation of "Buy" by Analysts - MarketBeat
Theravance Biopharma stock hits 52-week high at 20.69 USD By Investing.com - Investing.com Nigeria
Theravance Biopharma stock hits 52-week high at 20.69 USD - Investing.com
Trading the Move, Not the Narrative: (TBPH) Edition - Stock Traders Daily
Theravance Biopharma (NASDAQ:TBPH) Sets New 12-Month HighWhat's Next? - MarketBeat
Theravance Biopharma CEO earns 2026 Honorable Mentor title - Traders Union
Theravance Biopharma, Inc. Announces Upcoming Phase 3 Data for Ampreloxetine - TradingView — Track All Markets
Theravance Biopharma, Inc. (TBPH) Stock Analysis: Unpacking A 40% Potential Upside - DirectorsTalk Interviews
What valuation ratios show for Theravance Biopharma Inc. (0TB) stockJuly 2025 Technicals & Reliable Entry Point Alerts - Улправда
Chart Watch: What valuation ratios show for Theravance Biopharma Inc. (0TB) stockWeekly Trend Recap & Smart Investment Allocation Tips - Улправда
Will Theravance Biopharma Inc. stock deliver better than expected guidanceMarket Activity Summary & Verified Momentum Stock Ideas - Улправда
Published on: 2026-01-08 18:37:29 - Улправда
mF International, Theravance Biopharma And Other Big Stocks Moving Lower In Monday's Pre-Market Session - Benzinga
Theravance Biopharma (NASDAQ:TBPH) Share Price Crosses Above Fifty Day Moving AverageWhat's Next? - MarketBeat
Theravance Biopharma (NASDAQ:TBPH) Share Price Crosses Above Fifty Day Moving Average – What’s Next? - Defense World
(TBPH) Volatility Zones as Tactical Triggers - Stock Traders Daily
Theravance Biopharma (NASDAQ:TBPH) Lowered to Buy Rating by Wall Street Zen - MarketBeat
Portfolio Update: Why Theravance Biopharma Inc 0TB stock stays resilient2025 Short Interest & Daily Entry Point Alerts - moha.gov.vn
Can Theravance Biopharma's Ampreloxetine Fill The Gap In MSA-Related NOH Therapy? - RTTNews
Market Overview: Is Theravance Biopharma Inc stock trading near support levels2025 Macro Impact & Weekly Return Optimization Plans - Bộ Nội Vụ
What drives Theravance Biopharma Inc stock priceMarket Insider Reports & Build Your Portfolio With Our Free Stock Scanner - earlytimes.in
Inspire Investing LLC Purchases New Position in Theravance Biopharma, Inc. $TBPH - MarketBeat
Here's Why Theravance Biopharma (TBPH) is a Strong Growth Stock - sharewise.com
(TBPH) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
Wall Street Analysts Believe Theravance Bio (TBPH) Could Rally 42.15%: Here's is How to Trade - Finviz
Finanzdaten der Theravance Biopharma Inc-Aktie (TBPH)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.24%
0.19%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):